On Tuesday, Aditxt Inc.
(NASDAQ:ADTX) said its wholly owned subsidiary, Ignite Proteomics, signed a definitive business combination agreement that values the precision oncology company at approximately $150 million.
The transaction is expected to separate Ignite from Aditxt and establish it as an independent public company through a newly formed holding company, expected to be named Ignite Proteomics Inc.
Aditxt is expected to remain a separate Nasdaq-listed company, subject to continued compliance with Nasdaq listing requirements.
Following the deal's completion, Ignite and the acquisition corporation are expected to become wholly owned subsidiaries of the new holding company.
